RCS - Yourgene Health PLC - DPYD kits recommended by NHS England

Yourgene HealthAnnouncement

02/12/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201202:nRSB1916Ha&default-theme=true

RNS Number : 1916H  Yourgene Health PLC  02 December 2020

 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

DPYD kits recommended by NHS England

 

Manchester, UK - 2 December 2020: Yourgene (AIM: YGEN), the international
molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy
Statement, published by NHS England, titled: 'Pharmacogenomic testing for DPYD
polymorphisms with fluoropyrimidine therapies' recommending the routine
availability of DPYD testing prior to the start of treatment with
chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe
side effects.

 

This statement supports the use of Yourgene's oncology product, Elucigene
DPYD* test, which is already routinely being used in Wales, as previously
announced on 12 October 2020. There are seven Genomic testing hubs in the NHS
and currently three out of the seven are using the Company's DPYD kits.

 

The full report can be found here: NHS England » Clinical Commissioning
Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with
fluoropyrimidine therapies
(https://www.england.nhs.uk/publication/clinical-commissioning-urgent-policy-statement-pharmacogenomic-testing-for-dpyd-polymorphisms-with-fluoropyrimidine-therapies/)

 

Lyn Rees, CEO of Yourgene, commented: "We are thrilled to see NHS England
issue this statement, recommending that DPYD testing is routinely carried out
prior to cancer treatment, highlighting the importance of such test and
improving care for cancer patients. It's rewarding to see this has been
published so soon after becoming the sole supplier of DPYD in Wales and we
look forward to seeing this market grow further."

 

 

*Elucigene DPYD is a simple-to-use genotyping test that can identify cancer
patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can
cause severe and sometimes lethal side effects in patients being treated with
chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of
colon, oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU is
metabolized by the DPD enzyme which is encoded by the DPYD gene.

 

 

 

 

 Yourgene Health plc                                                           Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                                             investors@yourgene-health.com
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 N+1 Singer (Joint Corporate Broker)                                           Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                       Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
  Paul McManus / Lianne Cawthorne                                              Mob: 07980 541 893 / Mob: 07584 391 303

 

 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops
and commercialises genetic products and services. The group works in
partnership with global leaders in DNA technology to advance diagnostic
science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADFLFBBLLZFBZ